Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials.

Although the addition of palbociclib to fulvestrant led to an absolute OS prolongation of 7.4 months, this difference did not reach statistical significance within the follow-up period (hazard ratio = 0.79, 95% CI 0.60–1.04, p = 0.093; log-rank p = 0.093; Fig. 2 ; Appendix p 6 ).

also in 111,027 other papers